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Mother-to-child transmission of HIV (MTCT) depends on the timing of HIV infection. We esti-
mated HIV-seroconversion during pregnancy (HSP) after having a HIV-negative result ante-
natally, and its contribution to early MTCT in South Africa (SA).
Methods and Findings
Between August 2011 and March 2012, we recruited a nationally representative sample of
mother-infant pairs with infants aged 4-to-8 weeks from 578 health facilities. Data collection
included mother interviews, child health-card reviews, and infant dried-blood-spots sample
(iDBS). iDBS were tested for HIV antibodies and HIV-deoxyribonucleic-acid (HIV-DNA).
HSP was defined as maternal self-report of an HIV-negative test during this pregnancy, no
documented use of antiretroviral drugs and a matched HIV sero-positive iDBS. We used 20
imputations from a uniform distribution for time from reported antenatal HIV-negative result
to delivery to estimate time of HSP. Early MTCT was defined based on detection of HIV-
DNA in iDBS. Estimates were adjusted for clustering, nonresponse, and weighted by SA’s
2011 live-births.
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Results
Of 9802 mother-infant pairs, 2738 iDBS were HIV sero-positive, including 212 HSP, result-
ing in a nationally weighted estimate of 3.3% HSP (95% Confidence Interval: 2.8%-3.8%).
Median time of HIV-seroconversion was 32.8weeks gestation;28.3% (19.7%- 36.9%) esti-
mated to be >36 weeks. Early MTCT was 10.7% for HSP (6.2%-16.8%) vs. 2.2% (1.7%-
2.8%) for mothers with known HIV-positive status. Although they represent 2.2% of all moth-
ers and 6.7% of HIV-infected mothers, HSP accounted for 26% of early MTCT. Multivariable
analysis indicated the highest risk for HSP was among women who knew the baby’s father
was HIV-infected (adjusted-hazard ratio (aHR) 4.71; 1.49-14.99), or who had been
screened for tuberculosis (aHR 1.82; 1.43-2.32).
Conclusions
HSP risk is high and contributes significantly to early MTCT. Identification of HSP by repeat-
testing at 32 weeks gestation, during labor, 6 weeks postpartum, in tuberculosis-exposed
women, and in discordant couples might reduce MTCT.
Introduction
Current guidelines in South Africa (SA) recommend testing pregnant women for human
immunodeficiency virus (HIV) antibodies at the first antenatal care visit, retesting at 32 weeks
gestation and again at labor, with the goal of this testing being the early identification of both
existing undiagnosed HIV infection as well as incident infections occurring during pregnancy.
[1] This testing intervention, combined with the 2013 World Health Organization (WHO) rec-
ommendations for early initiation of triple antiretroviral therapy (ART) as soon as HIV infec-
tion is identified in pregnant and breastfeeding women, is crucial to preventing mother to child
transmission of HIV (PMTCT), preserving the mother’s health and reducing the number of
HIV-infected children.[2] Even when a mother’s HIV infection is discovered late in pregnancy
or at birth, the use of ART coupled with other interventions such as exclusive breastfeeding
could result in substantial reductions in mother to child transmission (MTCT).[3, 4]
It has been hypothesized that the risk of MTCT may be higher for HIV-infected women
who become infected during pregnancy than for those who are seropositive before pregnancy.
[5] Levels of circulating HIV virus are known to be higher in the first few weeks of infection [6,
7], and typically remain high for the first 3–4 months after infection.[8, 9] Furthermore, the
volume of maternal blood that a pregnant woman exposes her fetus to, through the placenta,
increases throughout pregnancy. Thus the risk of MTCT could depend on the timing of HIV
infection, the concentration of HIV in her blood and the amount of blood to which the fetus is
exposed.[10] Few studies have been able to document such a relationship [10–12], and those
that do [10–11] could not identify the time when incident infections occurred during pregnan-
cy. Although several observational studies in Malawi and Uganda show that rates of incident
HIV infection were higher in pregnant women than non-pregnant women, none of these stud-
ies identified risk factors for incident infection that could be used to develop practical public
health interventions.[11–13]
We aimed to estimate population-based risks of HIV seroconversion of women during
pregnancy after having a HIV-negative result antenatally and its contribution to early MTCT
risk and HIV prevalence in infants aged 4–8 weeks at national level. Further, we estimated the
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timing of the seroconversions in order to inform recommendations for optimal retest time-
points and identified risk factors to recommend potential interventions to reduce maternal in-
cident infections during pregnancy.
Methods
This study was nested within the evaluation of the effectiveness of the national PMTCT pro-
grams in SA (SAPMTCTE) which aimed to estimate MTCT risks and HIV prevalence in in-
fants aged 4–8 weeks. Between August 2011 and March 2012, we conducted a facility-based
survey designed to recruit a representative sample of infants aged 4–8 weeks from all nine prov-
inces in SA.
Study design
A total of 12200 participant samples were desired to measure the HIV prevalence among the
4–8 week infant population and MTCT risk measured at 4–8 weeks postpartum (early MTCT)
at a confidence interval (CI) width of 1% to 2%, varied by province (S1 Table). Since annual
coverage of the first Diphtheria/Tetanus/Pertussis vaccinations was>95% of live-births in SA,
we estimated the number of HIV-exposed infants attending each facility for the first DPT vac-
cine doses, and the HIV prevalence among pregnant women attending the 1st antenatal care
(ANC) visit for the district where the facility was located. Our primary sampling unit, the
health facility, was stratified into three strata providing (1)>300 infants receiving1st DPT an-
nually and located in a district with antenatal HIV prevalence 29% (the national ANC HIV
prevalence), (2)>300 infants receiving the first DPT annually and located in a district with an-
tenatal HIV prevalence<29%, and [3] 130–300 infants receiving the first DPT annually re-
gardless of HIV prevalence. A total of 580 primary health facilities (ranging from 33 to 79
facilities per province) were randomly selected from 25 strata, representing each stratum and
each of the nine provinces with probability proportional to size (PPS) method.[14] At the time
of recruitment two selected study sites were undergoing renovations, and their clients were
being referred to other facilities in the area which also had a possibility of being selected in the
sample, so that data were collected from 578 total facilities. We determined the total number of
infant dried-blood-spots (iDBS) samples for each selected facility proportionally to number of
infants receiving the first DPT at the facility annually (S1 Table). Eligible caregiver/mother and
infants pairs were consecutively selected from facilities from each stratum over three-weeks
(four weeks in one province).
For each caregiver-infant pair, a trained nurse conducted a face-to-face interview with the
caregiver using a standardized questionnaire, reviewed the child health card (CHC) and had an
iDBS sample collected for HIV testing.
For this analysis, we only included mother-infant pairs in which the mother had 1 ante-
natal care (ANC) visit and their infants aged 4–8 weeks had provided an appropriate iDBS
sample for HIV testing. We assessed current socio-demographic and socio-economic charac-
teristics, and collected data on ANC, labor/delivery including gestational age at delivery, infant
birth weight, all prior HIV testing history, PMTCT/ART interventions received, and partner’s
HIV status. The mothers who reported being tested for HIV and receiving HIV-negative results
during this pregnancy were asked the time (gestational age) of their last HIV test. We extracted
data related to PMTCT interventions from each infant’s health chart.[15] Data were collected
using pre-programmed handheld devices (cell-phones) and interview data were uploaded real-
time into a web-based database.[16]
Pre-test counseling and parental consent was conducted and iDBS were obtained from in-
fants from heel prick blood draw onto Munktell-TFN 5-spot paper. Infant test results were
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returned to participants using routine national systems; de-identified results were captured in
the study database.
Laboratory Testing
All iDBS samples were tested in the National Institute for Communicable Diseases, National
Health Laboratory Services, Johannesburg, using standardized procedures. iDBS underwent se-
rologic testing for HIV antibody using an enzyme immunoassay (EIA) [Genscreen HIV1/2 Ab
EIA Version 2, Bio-Rad Laboratories, France]. All antibody-positive and 10% of negative speci-
mens were re-tested using a second EIA [Vironostika HIV Uni-form II plus O, bioMḕrieux
Clinical Diagnostics, Marcy-L’Etoile, France]. Specimens with discordant results were tested
with and HIV-1Western blot [GS HIV-1, Bio-Rad France] and in all such cases (n = 4) the
Western blot was negative and considered definitive.
iDBS specimens with concordant positive or discordant EIA results and from self-
reporting HIV-positive mothers were tested using a qualitative deoxyribonucleic acid (DNA)
Polymerase Chain Reaction (PCR) to determine infant’s HIV infection status [COBAS
AmpliPrep/COBAS TaqMan—CAP/CTM—Qualitative assay version 1.0 assay, Roche Diag-
nostics, Branchburg, NJ]. Confirmed antibody-positive specimens indicated HIV-exposed
infants (HEI). EIA and PCR-positive infants were defined as having confirmed early
HIV infection.
Definitions of the mother’s HIV status during pregnancy
We used a composite of maternal self-report, the iDBS test result and information from the
CHC to minimise bias in the classification of HIV status of mother’s due to self-report. In
our sample 93% of mother-infant pairs had a CHC at interview; 61% of mother’s who self-
reported as HIV-infected and 46% of those who reported their test result as HIV-negative
had this documented on the CHC. Further 63% of mother’s who self-reported as HIV-
infected had documentation of child prophylaxis on the CHC compared to less than 5% of
those who reported being HIV-negative; mothers in this last group were considered to not
have definitive information on HIV testing during ANC and were excluded from the sero-
conversion analysis (Fig 1). The remaining 9802 mother-infant pairs were categorized as
follows:
1. Mothers with HIV-negative status throughout pregnancy: Mothers who met following four
criteria (a) reported being tested for HIV, and (b) receiving HIV-negative result during this
pregnancy, and (c) whose infant’s CHC did not record any HIV infection/exposure or any
antiretroviral intake, and (d) whose iDBS collected at 4–8 weeks postpartum were negative
for HIV antibodies (negative with HIV EIA test, or Western blot)
2. Mothers with known (prevalent) HIV infection during pregnancy: Mothers who reported
having HIV-positive status diagnosed prior to this pregnancy or during pregnancy (at any
ANC visits or at labor)
3. Mothers with seroconversion during pregnancy: Mothers who met following three criteria
(a) reported being tested for HIV and having an HIV-negative result as the result of the lat-
est test during this pregnancy, and (b) whose infant’s CHCs did not record any HIV infec-
tion /exposure or any antiretroviral intake, and (c) their iDBS collected at 4–8 weeks
postpartum were positive for HIV antibodies (positive with two different HIV EIA tests, or
Western blot)
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Statistical Methods
Data were analyzed as a retrospective cohort. Since HIV-positive pregnant women could only
transmit HIV antibodies to their fetus through the placenta and the antibodies remain in HEI
blood for an average of 13 weeks after delivery [17, 18], the mothers of infants with iDBS that
were positive with HIV antibodies would have had positive HIV test results if they had been
tested at delivery. We used these well-established data to impute seroconversion times in both
Fig 1. Profile of the evaluation of the effectiveness of the National Prevention of Mother-to-child transmission of HIV of the nested analysis of the
maternal incident infection during pregnancy in South Africa, 2011–2012.
doi:10.1371/journal.pone.0125525.g001
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descriptive analysis of the time to seroconversion as well as multivariate survival models that
assessed the effect of potential risk factors on seroconversion as described below. We imputed
time of seroconversion using a uniform distribution to assign an equal probability of serocon-
version to each day between gestational age at delivery (the follow-up time-point to detect sero-
conversion) and the last reported negative HIV test during pregnancy (baseline time-point).
To add variability to this imputation we repeated this procedure 20 times and calculated
Kaplan-Meier cumulative incidence estimates using Taylor series linearization methods to cal-
culate standard errors of the estimates to account for the survey design [19] and the methods
of Rubin [20] to accounting for variance due to multiple imputation when estimating time of
seroconversion. We did not directly ask about repeat testing during pregnancy, but estimated
the proportion of mother’s who reported the latest negative HIV test obtained at or after 32
weeks gestation, as well as the proportion of mothers who reported that the latest negative test
obtained after 32 weeks gestation was also more than 8 weeks after their first ANC visit, a po-
tential marker for retesting according to the SA national PMTCT clinical guidelines.[1]
Multivariate analyses that again accounted for the survey sample design [19] in variance cal-
culations were used to identify risk factors for HIV seroconversion included both a model for
log odds of HSP, and a proportional hazards model for the time to seroconversion. Based on
findings from previous studies, we considered a variety of possible confounders of the effects of
covariates on HSP including characteristics of the mother (marital status, education, socio-
economic status, age), pregnancy-related factors (gestational age at first antenatal visit, total
number of ANC visits, testing for syphilis or whether the mother was screened for tuberculosis
during this pregnancy, infant’s birth-weight, parity and number of live-children, where the
baby was delivered, and who attended the birth) and partner’s HIV status in this analysis. The
socio-economic status variable (SES) was a composite variable constructed using a clustering
algorithm that considered 10 interview items (see S2 Table for a detailed description of the con-
struction of this variable). Mother’s age, the number of ANC visits, total numbers of pregnan-
cies and live-births, and infant birth-weight were included in bivariate and multivariate
analyses as continuous variables; all other variables were categorical. Mother’s current marital
status, SES, number of live-births, maternal HIV knowledge, where the baby was delivered and
infant’s birth-weight did not change the effect by>10% from the full model (see S3 Table for
the full model) and were not included in the final/reduced model.
Survey analysis methods employing Taylor series linearization for variance estimation were
used to account for the sampling design including clustering of responses within facilities,
stratification (for each of nine provinces, the study population was divided into strata based on
number of administrations of the first DPT at each facility, HIV prevalence among the 1st
ANC visit in the prevalence—see the sampling section for more details) and non-response
[19]. We treated all selected facilities that did not achieve the desired sample size (study sam-
ple), and the two clinics undergoing renovation where no participants could be recruited as
non-responses in our analysis. Since this study was designed as a survey to recruit a national
representative sample of infants aged 4–8 weeks, and given 98% of live-infants received the
first DPT,[21] we used the distribution of numbers of live-births across the nine provinces in
SA in 2011 to weight our estimates to population-level.[22]
All statistical analyses were carried out using SAS [version 9.3, SAS Institute, Cary, NC]
and/or SUDAAN [Version 11.0.0, RTI International, Research Triangle Park, NC].
The protocol was approved by the United States Centers for Disease Control and Prevention
(CDC), and by the institutional review board of the SA Medical Research Council (MRC). All
participating caregivers and mothers provided written informed consent for themselves and
their children. All consent forms were recorded in real-time during the interview using our
study mobile devices and signed hard-copy consent forms were kept at the SAMRC in Cape
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Town per the approved protocol. All HIV test results were returned to participating mothers/
caregivers through the clinic nurses as part of the routine services.
Results
Of 10763 eligible infants, we recruited a total of 10106 (93.9%) mothers/caregivers from 578 fa-
cilities who consented to participate in the SAPMTCTE and whose iDBS specimen was suffi-
cient for HIV testing. There were no significant differences at p-value of 0.05 in the
distribution of province, mothers’ age, educational-level, the infants’ age or gender between the
eligible infant-caregiver pairs who either refused to participate in the interview (n = 288) or to
provide iDBS (n = 330), or whose iDBS samples were not sufficient for HIV testing (n = 39)
and those who consented to participate to both sections (interviews and iDBS) of the study
(Fig 1). Further, we excluded 304 mother/infant pairs who were either accompanied by caregiv-
ers who were not mothers or where the mother did not receive any ANC visit during pregnancy
or where the mother’s self-report of HIV-negative status was refuted by a record of HIV treat-
ment on the CHC. As a result, a total of 9802 infants aged 4–8 weeks and their mothers who
had 1 ANC visit were eligible to be included in this analysis (Fig 1). Comparing the 304 ex-
cluded participants (3%) with the final sample (Table 1), the majority of the exclusions were
caregivers (297/304; 54% were the child’s grandparent) and they reported that the mothers
were significantly (p<0.05) younger (median age 21years), and more likely to be single (86%)
but were not different (p>0.05) in terms of the distribution of the SES composite variable or
proportion reporting vaginal delivery.
Our weighted findings show that 30.0% (95%CI 28.4%–32.0%) of mothers were HIV-
positive when pregnant. Of the mothers who reported having at least one ANC visit, being test-
ed for HIV, and having an HIV-negative status as the latest HIV test result during pregnancy,
and whose infant CHCs did not record any HIV infection /exposure or any antiretroviral expo-
sure, 3.3% (95%CI 2.8%–3.8%) seroconverted before giving birth to the infant.
Table 1 shows characteristics of the study population divided into three groups based on the
HIV status of the mother using the case definitions described in the method section: mothers
with HIV seroconversion during pregnancy; mothers with known HIV-positive status (preva-
lent cases); and mothers with HIV-negative status throughout pregnancy. All three groups
were made up of mostly multiparous, single women, of average composite SES status, who
completed education through Grade 8, had the same mean number of pregnancies and live-
births, and whose infants had similar mean birth- weight. Although all women reported having
similar mean gestational age at first ANC (approximately 18 weeks), mothers with HIV-nega-
tive status throughout pregnancy as well as those with HIV seroconversion reported that they
received the results of their last HIV test at a mean gestational age of 24.5 weeks and 25 weeks,
respectively. Compared with mothers with HIV-negative status throughout pregnancy, moth-
ers with known HIV-positive status during pregnancy were older (mean age 28 vs. 25 years),
had a similar number of ANC visits (5.1 vs. 4.9), and were more likely to be screened for tuber-
culosis during the pregnancy (49.7% vs. 32.2%). Similarly, mothers with HIV seroconversion
during pregnancy were older (mean age 26.6 vs. 25 years), more likely to report being screened
for tuberculosis during this pregnancy (46.8% vs. 32.2%) and less likely to have had a delivery
attended by a physician (22% vs. 25.9%) compared to those mothers with HIV-negative status
throughout pregnancy. However, mothers with HIV seroconversion had fewer ANC visits (4.3
visits) compared to either mothers who reported being HIV-positive (5.1 visits) or those moth-
ers with HIV-negative status throughout pregnancy (4.9 visits). A low percentage of both
mothers who did (21.8%) and did not (22.7%) seroconvert reported testing negative at or after
32 weeks gestation. Similar and even lower percentages (15.8% and 16.4%, respectively)
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Table 1. Socio-demographic characteristics of participating mothers and infants by maternal HIV status during pregnancy, South Africa, 2011–
2012.
Mothers with HIV seroconversion
during pregnancy
Mothers with known (prevalent) HIV-
positive status prior or during
pregnancy *














































Widow/Divorced 134 (2) 0.5 (0.2–2.7) 2,160 (20) 0.6 (0.4–1.0) 3,073 (31) 0.4 (0.2–0.6)
Education level
None 307 (4) 1.2 (0.2–3.8) 4,879 (41) 1.4 (1.0–2.0) 11,606 (104) 1.5 (1.2–1.9)
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reported an HIV-negative test that both occurred at or after 32 weeks and that was more than 8
weeks after their first ANC visit. The proportion of mothers who reported knowing the father’s
HIV status was low across all three groups, lowest among mothers with HIV-negative status
throughout pregnancy (52%) and highest in women with seroconversion (66%). Of those who
reported knowing the partner’s HIV status, 50.2% of women with known HIV-positive status
during pregnancy, 2.2% of women with seroconversion, and 1.3% of mothers who were HIV-
negative throughout pregnancy reported the father of the child was HIV-infected.
Although mothers with HIV seroconversion during pregnancy represent 6.7% (95%CI:
5.7%–7.8%) of all pregnant mothers infected with HIV (or HIV-exposed infants perinatally),
these mothers account for 26.0% (95%CI: 17.1%–36.6%) of early MTCT cases in SA (Fig 2).
Mothers who self-reported not testing for HIV or having unknown HIV status represent 2.8%
(95%CI: 1.7%–4.3%) of the HIV prevalence (all mothers), and account for 3.9% (95%CI: 0.9%–
10.3%) of early MTCT cases.
When comparing mothers who were HIV-negative throughout pregnancy and those with
HIV seroconversion during pregnancy (Table 2), the highest risk for acquiring infection was
for those mothers who reported knowing that the baby’s father was HIV infected (adjusted
Hazard Ratio (aHR) 4.71; 95%CI 1.49–14.99). Having lower than average education (through
grade 7 compared to those who had>12 years of education) (aHR 2.4; 95%CI 1.02–5.67),
being screened for tuberculosis during pregnancy (aHR 1.82; 95%CI 1.43–2.32), and each year
increase of maternal age (aHR 1.06; 95%CI 1.03–1.08) also significantly increased the risk of in-
cident infection. Each additional follow-up ANC visit (aHR 0.90; 95%CI 0.83–0.97) and having
the birth attended by a nurse (0.55; 95%CI 0.31–0.96) or doctor (aHR 0.49; 95%CI 0.27–0.90)
reduced the risk of incident infection during pregnancy.
Table 1. (Continued)
Mothers with HIV seroconversion
during pregnancy
Mothers with known (prevalent) HIV-
positive status prior or during
pregnancy *




























































*20 mothers who reported taking or having antiviral-drugs documented in the child health card reported “unknown HIV status were considered as “HIV-
infected at or before current antenatal visit);
N** = weighted number for the live-birth in South Africa in 2011
n*** = actual number of the study participants
ND**** = Not documented/collected
doi:10.1371/journal.pone.0125525.t001
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Based on reported gestational age at the last known negative HIV test result during preg-
nancy and at delivery, we estimated that the mean time of the HIV seroconversion during preg-
nancy was 31.8 weeks gestation (95%CI: 30.7–32.9). Additionally, we estimated that 28.3%
(95%CI: 19.7–36.9) of women were infected after week 36 of gestation (Fig 3).
Fig 4 shows that early MTCT risk among mothers with HIV seroconversion during preg-
nancy was significantly higher than that observed among those mothers known to be HIV-pos-
itive during pregnancy (10.7% (95%CI: 6.2%–16.8%) vs. 2.2% (95%CI: 1.7%–2.8%), p<0.01).
Considering the estimated time of HIV seroconversion, we found that early MTCT risk was
similar between the group of mothers whose seroconversion occurred 32 weeks of gestation,
(the recommended retest time point for those with an HIV-negative results in SA), and those
mothers estimated to have acquired HIV infection before 32 weeks (12.0%vs. 9.5%, p>0.05).
Discussion
Results from this study show that, in 2011–2012, an estimated 3.3% (n = 25 061) of mothers in
SA who had at least one HIV-negative test result antenatally seroconverted during pregnancy.
Compared with the national estimate of 1.5% HIV incident infection risk among women aged
15 to 49 years in SA (2005–2008)[23], and with the 2.8% risk estimated by Rehle group [24],
our finding indicates that pregnant women have a higher risk of acquiring HIV in pregnancy.
Fig 2. Weighted relative proportion of maternal HIV seroconversions during pregnancy and early mother to child transmission of HIV (MTCT) by
time of maternal HIV infection identified group, South Africa, 2011–2012. This figure shows the distribution of awareness of HIV infection for all HIV-
infected mothers, and for all mothers who transmitted HIV-infection to their infants. Mothers are categorized as a) knowing they were infected prior to this
pregnancy (solid black) b) newly identified as HIV-infected during this pregnancy (upward diagonal lines) c) identified as HIV-infected by testing of infant dried
blood spot specimens after reported not knowing their HIV status in our survey (solid grey box) and d) identified as HIV-infected by testing of iDBS after
reporting testing HIV-negative in our survey, and with no other evidence of HIV infection reported on the infants child health card (light grey downward
diagonal lines). Percentages are adjusted for the sampling design including clustering, design effects and nonresponse, and weighted to the population
distribution of live-births for South Africa (SA) in 2011. It shows that, although women who seroconverted after a negative HIV test represent only 6.7% of the
population of HIV-infected pregnant women in SA in 2011, these mothers accounted for 26.0% of all maternal to child transmission of HIV.
doi:10.1371/journal.pone.0125525.g002
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The finding supports Moodley et al [25, 26], who reported 3.0% risk of incident infection be-
tween the first ANC visit and 36–40 weeks of gestation in three provinces of SA. Similarly,
Kinuthia et al [27] reported higher (2.6%) risk during pregnancy than during breastfeeding in
Kenya. Gray et al [11] also reported a higher risk during pregnancy (2.1%) as compared with
non-pregnant or breastfeeding women (1.2%) in Uganda.
We also found that less than 60% of the mothers knew the HIV status of the infant’s fathers
during pregnancy, indicating very low rates of HIV disclosure among sexually active couples.
Although only 2.2% of women with HIV seroconversion during pregnancy reported the in-
fant’s father was HIV-positive, their risk of acquiring HIV increased by 4.7 fold (aHR = 4.71)
compared with women with a reported HIV-negative partner. We believe that the actual risk
of HIV acquisition due to discordance (HIV-negative pregnant women and HIV-positive male
sex-partner) during pregnancy may be much higher than our measurement because many fa-
thers whose female partners did not know their status may have not been diagnosed or dis-
closed HIV infection, which partially explains the elevated risk for HIV seroconversion
(aHR = 1.88) within this group of mothers. These findings support the WHO recommendation
of offering couples counselling and testing to all pregnant women at PMTCT settings.

















Each additional year in mother’s age 1.06 1.03 1.09 1.06 1.03 1.08
Each additional ANC visit (over 1) 0.89 0.77 1.03 0.90 0.83 0.97
Maternal education completed
No Education 2.83 1.22 0.35 4.24 1.22 0.36 4.14
Grade 1–7 5.09 2.45 1.02 5.85 2.40 1.02 5.67
Grade 8–12 3.18 1.86 0.84 4.15 1.84 0.83 4.05
>12 years 1.57 Ref. Ref.
Baby’s father HIV status
HIV-negative 2.18 Ref. Ref.
HIV-infected 10.74 5.03 1.45 17.41 4.71 1.49 14.99
Don’t know 4.31 1.91 1.42 2.55 1.88 1.41 2.51
Tuberculosis screening during
pregnancy
Yes 4.64 1.81 1.41 2.32 1.82 1.43 2.32
No Ref Ref.
Birth attendant
Traditional healer/home delivery 6.69 Ref. Ref.
Nurse/Midwife 3.33 0.52 0.29 0.94 0.55 0.31 0.96
Doctor 2.70 0.47 0.25 0.88 0.49 0.27 0.90
*Adjusted for all listed covariates, total pregnancies including the index pregnancy, and the amount of support the mother reported receiving during
pregnancy weighted to account for sampling design and non-response, and with variance estimation via Taylor series linearization to account for sampling
design (see methods). Other potential confounders of the effects listed in this table, including mother’s marital status, Socio-economic status, number of
living children, maternal knowledge of modes of HIV transmission, whether the infant was born at home, in a hospital or clinic and birth weight of the baby
in kilograms were assessed but did not change the reported effects by more than 10% from the full model (see S3 Table) and therefore are not included in
the final model presented above.
doi:10.1371/journal.pone.0125525.t002
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Although data on sexual behaviors were not collected in our study, other investigators [11]
reported that of 3134 pregnancies in Uganda, 84% reported being sexually active during preg-
nancy and only 1% of pregnant women reported using a condom consistently during pregnan-
cy. Moodley et al [26] also reported that amongst HIV-seroconverted pregnant women only
3.0% reported not having sex and only 2.8% reported using a condom during pregnancy. These
findings again suggest that women in discordant couples were at significantly higher risk of ac-
quiring HIV during pregnancy. A multi-country clinical trial [28] has provided strong evidence
for the WHO recommendation [2] that HIV-positive partners in sero-discordant relationships
should take ARVs and use condoms to reduce the risk of HIV incident infections in their part-
ners. Additionally, encouraging HIV-negative women to use condoms during the pregnancy
and breastfeeding to prevent horizontal transmission has also been recommended as part of
HIV post-test counselling guidance as an early and effective measure before their sexual part-
ner’s HIV-status is confirmed. There are limited studies on accessibility and acceptability of
condoms among pregnant women, and the public health feasibility of this approach. A study
in the United States [29] showed that there was a significant increase in condom use in preg-
nant women at high risk for sexually transmitted disease (from 33.3% to 84.6%) when condoms
were accessible and distributed free of charge, along with health education.
Fig 3. Estimated time of seroconversion for mothers with a negative HIV test result during PMTCT but became infected during their current
pregnancy, South Africa, 2011–2012. This figure shows the results of a Kaplan-Meier (KM) time to event analysis of the time of seroconversion for 20
imputations of the weighted sample of 25,061 mothers represented by 211 sampled mothers who tested negative for HIV during this pregnancy and then
became infected before they delivered their baby. Dashed lines represent the individual KM estimates for each of 20 imputations of the time of
seroconversion, and the dark black line is the mean of these imputations. Median time of seroconversion was estimated to be 32.8 weeks of gestation,
ranging from 31.5 to 33.6 across the imputations.
doi:10.1371/journal.pone.0125525.g003
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We found that mothers had an 81% increased risk of HIV seroconversion if they underwent
tuberculosis screening. Under the guidelines at the time in SA (the 2010 PMTCT clinical guide-
lines) [1] these women were likely to have reported being exposed to tuberculosis or have tu-
berculosis symptoms, resulting in the offer of screening. We also found that a significantly
higher proportion of mothers who reported having HIV-positive status reported being
screened for tuberculosis during pregnancy compared with those mothers with reported HIV-
negative status throughout the pregnancy (49.7% vs. 32.2%). Since we did not record tubercu-
losis cases identified through the screening as well as history of the tuberculosis exposure, we
could not establish the causal pathway between tuberculosis and HIV seroconversion within
this study. However, we believe provision of a package of both tuberculosis screening and HIV
testing [30] would improve early detection of both HIV infections, including incident infection,
and tuberculosis infection, especiallyin settings with high prevalence of both HIV and tubercu-
losis like SA.
Since we recruited infants aged 4 to 8 weeks from August 2011 to March 2012, our partici-
pating mothers first received ANC and PMTCT services provided within November 2010 to
June 2011, under the 2010 national PMTCT guidelines.[1] This means that pregnant women
Fig 4. Weighted risk of early mother to child transmission amongmothers with HIV seroconversions during pregnancy compared to mothers with
reported HIV-positive status prior to the current pregnancy. This figure illustrates the estimate (diamonds) and 95% confidence intervals (vertical lines)
for the proportion of HIV-infected mothers who had transmitted HIV to their infants by 4–8 weeks postpartum. Proportions are adjusted for the survey
sampling design including clustering, design effects and nonresponse, and weighted to the population distribution of live-births for South Africa (SA) in 2011.
The left panel of the graph shows a significantly higher proportion of mothers who seroconverted during pregnancy transmitted HIV to their infants than did
mothers whose HIV infection was known to them before or during this pregnancy. The right panel subsets the women who seroconverted during pregnancy
by the estimated week of gestation in which they seroconverted. Estimates of time of seroconversion were imputed using a uniform distribution to assign an
equal probability of seroconversion to each day between delivery and the last reported negative HIV test during pregnancy. The graph shows results based
on combined analysis of 20 imputations of this variable, and shows that the confidence intervals for the estimated proportion of mothers transmitting to their
infants did not differ whether the mother was estimated to have seroconverted before or after 32 weeks gestation.
doi:10.1371/journal.pone.0125525.g004
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should have been offered an HIV test at the first ANC visit and those who were HIV-negative
should have been offered another HIV test at 32 weeks gestation per the guidelines. However,
we found the mean of gestational age when these women received their last reported HIV-neg-
ative result was 25 weeks instead of 32 weeks gestation, and less than 17% reported a test at or
after 32 weeks that was also more than 8 weeks after their first ANC visit. A report of the na-
tional PMTCT program found that 98% of ANC attendees were tested for HIV at the first
ANC visit [21], but, many of these mothers are engaging ANC late and not enough of the
mothers who test HIV-negative early in pregnancy are being retested. We estimate that more
than 50% of the seroconversions we observed occurred after 32 weeks gestation; therefore, even
if they had been retested according to the current re-testing guidelines, these women would not
have been diagnosed with HIV before delivery. Since the risk of early MTCT was high and not
statistically different between those women with seroconversion before or after 32 weeks of ges-
tation, retesting not only at 32 weeks gestation, but also at 36 weeks and/or during labor could
help identify these women in order to administer ART before birth, and thereby help to reduce
the early MTCT in this group. Since ART can also reduce MTCT risk during breastfeeding, re-
testing during postpartum (i.e., at 6 weeks postpartum) could further reduce late MTCT.
Although maternal HIV seroconversions represented only 2.2% (n = 25 061) of all mothers
giving birth, they accounted for 26% of early MTCT infections in infants (of 10 330 HIV-
infected infants due to early MTCT, 2686 HIV-infected infants who acquired HIV infection
perinatally were born to 25061 mothers who seroconverted during pregnancy). If the HIV-
positive status of those seroconverted mothers were detected before giving birth, they could
have received proper ART immediately during pregnancy, labor, and throughout breastfeeding
to prevent MTCT and reduce the early MTCT risk from the current risk of 10.7% to as low as
2.2% (Fig 3). If HIV infection had been detected during pregnancy, the national PMTCT pro-
grams could have averted as much as 2135 additional HIV-infected infants aged 4–8 weeks,
and more during breastfeeding.
Our findings have some limitations. We were not able to estimate risk of HIV seroconver-
sion among those who acquired HIV after being pregnant but were diagnosed as HIV-positive
at the first or subsequent ANC visit(s). Additionally, our estimates did not include HIV expo-
sure or transmission among those infants whose mothers (3%—Fig 1) did not attend ANC nor
those who did not bring their infants to public health facilities for the first DPT immunization
(<5% of live-births). Our estimates were based on proportion of mothers who reported antena-
tal HIV-negative status verified by a lack of ARV and HEI documented in the infant’s routine
CHCs, and whose infant’s DBS were positive with HIV antibodies indicating the mother sero-
converted after the last known HIV-negative status. Only 46% of HIV-negative test results dur-
ing ANC were both reported by the mother and verified on the CHC. As a result, we may
overestimate the risk of HIV seroconversion if some women considered to have seroconverted
had failed to disclose their HIV infection during the interview and also had errors in documen-
tation of ARV use on the CHC. However, such mothers would still represent missed opportu-
nities for HIV diagnosis during pregnancy and be at increased risk of transmission because
they and their infant did not receive prophylaxis. Although we believe that the uniform distri-
bution approach is the most appropriate and conservative method to estimate time to serocon-
version, for example compared to an interval censored data approach analysis, we possibly
biased our estimates of timing of seroconversion by giving too much weight to the possibility
of infections acquired later in pregnancy if sex frequency were to go down toward the end of
pregnancy. However, while this might increase the proportion of infections detectable at week
32 of gestation, it is not likely to eliminate the possibility of seroconversion after this time peri-
od. The timing of seroconversion may be biased because the women may misreport the gesta-
tional age when the last negative test result was obtained (baseline time point); however, we
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don’t think this factor would bias our seroconversion risks. Estimates of association for risk fac-
tors of maternal seroconversion could be affected by both recall and social-desirability biases
resulting from maternal self-report. However, we are unable to predict either the magnitude or
the direction of these biases.
This is the first nationally representative estimate of the risk of HIV seroconversion among
women who had at least one HIV-negative test result during pregnancy in SA. The findings
highlight a few emergent priorities for the national PMTCT program including: repeat testing
at 32 and 36 weeks gestation, at labor, and 6 weeks postpartum; couples counseling and testing
and early initiation of ART for HIV-positive partners in sero-discordant partnerships; promo-
tion of using condoms during pregnancy; and provision of HIV testing and tuberculosis
screening as a package in ANC settings. Successfully implementing these interventions could
help in early detection of incident HIV infections occurring during pregnancy, and early initia-
tion of ART to reduce MTCT risk during pregnancy and breastfeeding.
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